sEphB4-HSA inhibits KS tumor growth in a murine tumor xenograft model. (A) Mice (n = 8/group) were implanted with 2 × 106 KS-SLK or KS-IMM cells and treated with sEphB4-HSA, VEGF moAb, or combination sEphB4-HSA/VEGF moAb; tumor volumes were measured 2 times a week; and the data are presented as tumor volume. After 5 weeks, tumor volumes were as follows; sEphB4-HSA (KS-SLK = 15.9% of control, P < .001; KS-IMM = 37.2% of control, P < .001) or combination sEphB4-HSA plus VEGF moAb (KS-SLK = 12.1% of control, P < .001; KS-IMM = 12.6% reduction, P < .001). (B) Mice spleens were injected with 106 SLK cells and treated with sEphB4-HSA, VEGF moAb, or combination sEphB4 plus VEGF moAb. After 5 weeks, livers were harvested and examined for the number of tumor metastases (tumors/livers) and are as follows; control (8/11), VEGF moAb (2/5), sEphB4-HSA (2/5), and combination of sEphB4-HSA and VEGF moAb (0/5).
